What is the recommended perioperative management of systemic psoriasis therapies for a patient undergoing coronary artery bypass grafting (CABG)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Perioperative Management of Psoriasis Therapies for CABG

For a psoriasis patient undergoing CABG (an intermediate-to-high-risk surgery), most systemic psoriasis therapies can be safely continued, but biologics with longer half-lives should be held approximately 3-4 half-lives before surgery and resumed 1-2 weeks postoperatively if no complications occur.

Risk Stratification

CABG is classified as an intermediate-to-high-risk surgical procedure because it involves entry into sterile body cavities and significant tissue manipulation 1. This classification is critical for determining medication management.

Medication-Specific Recommendations

Biologics (TNF-α inhibitors, IL-17, IL-23, IL-12/23 inhibitors)

  • Hold before surgery: Discontinue approximately 3-4 half-lives before the procedure 1
  • Resume after surgery: Wait 1-2 weeks postoperatively if no complications (wound healing normal, no infection) 1
  • Rationale: The 2024 National Psoriasis Foundation guidelines 2 indicate that while IL-17 inhibitors, IL-23 inhibitors, and ustekinumab are "likely safe to continue" for intermediate/high-risk surgery, a case-by-case approach is advised, and the more conservative AAD-NPF approach of holding these agents is prudent for major cardiac surgery

Methotrexate

  • Can be continued through CABG 2
  • The 2024 NPF guidelines specifically state MTX is likely safe to continue for intermediate- and high-risk surgery 2
  • Monitor for potential drug interactions with anesthesia medications

Cyclosporine

  • Can be continued through CABG 2
  • Critical caveat: Cyclosporine has significant drug interactions via CYP3A4 metabolism, particularly with calcium channel blockers, statins, and warfarin—all commonly used in cardiac surgery patients 3
  • Coordinate closely with the cardiac surgery team regarding these interactions
  • Monitor blood pressure and renal function closely perioperatively, as cyclosporine causes renal arteriole vasoconstriction 3

Apremilast

  • Can be continued through CABG 2
  • Minimal immunosuppression makes this safe to continue

Acitretin

  • Can be continued for any surgery 2
  • Does not affect wound healing or infection risk

JAK Inhibitors (tofacitinib, upadacitinib) and TYK2 Inhibitors (deucravacitinib)

  • Insufficient evidence to make firm recommendations 2
  • Conservative approach: Hold 3-5 half-lives before surgery given their immunosuppressive effects
  • Discuss risk-benefit with the surgical team

Practical Algorithm

Step 1: Identify all psoriasis medications the patient is taking

Step 2: Calculate timing based on drug half-life for biologics:

  • TNF-α inhibitors: Hold 3-4 weeks before surgery (most have 2-week half-lives)
  • IL-17/IL-23 inhibitors: Hold 8-12 weeks before surgery (longer half-lives)
  • Ustekinumab: Hold 12-15 weeks before surgery (3-week half-life)

Step 3: Continue methotrexate, cyclosporine, apremilast, and acitretin through surgery

Step 4: Alert cardiac surgery and anesthesia teams about cyclosporine if patient is taking it (drug interaction concerns)

Step 5: Resume biologics 1-2 weeks postoperatively if:

  • Wound healing is normal
  • No signs of infection
  • No other complications

Critical Pitfalls to Avoid

Drug interactions with cyclosporine: Patients on cyclosporine who require calcium channel blockers for blood pressure control perioperatively should receive isradipine, which does not interact with cyclosporine metabolism 3. Avoid thiazide diuretics (enhance nephrotoxicity) and potassium-sparing diuretics (risk of hyperkalemia) 3.

Premature biologic resumption: Do not restart biologics if there are any signs of wound complications or infection, even if 1-2 weeks have passed 1.

Assuming all systemic agents need to be stopped: This is outdated practice. The 2024 evidence 2 supports continuation of several agents even for major surgery.

Coordination of Care

Communicate directly with the cardiac surgery team about the patient's immunosuppressive regimen. The decision to hold or continue medications should involve shared decision-making considering the patient's psoriasis severity, surgical urgency, and individual infection risk factors 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.